Please login to the form below

Not currently logged in
Email:
Password:

Alecensa

This page shows the latest Alecensa news and features for those working in and with pharma, biotech and healthcare.

Pfizer’s ALK inhibitor Lorbrena scores expanded FDA approval for first-line NSCLC

Pfizer’s ALK inhibitor Lorbrena scores expanded FDA approval for first-line NSCLC

Lorbrena is also an important follow-up to Pfizer’s older ALK inhibitor Xalkori, which has come under pressure as it faces increasing competition from Roche’s Alecensa (alectinib) and Novartis’

Latest news

More from news
Approximately 16 fully matching, plus 24 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Four Health

Beautiful things happen when you put the right ingredients together. It’s the reason that we mix behaviour change experts with...

Latest intelligence

William Kilgallon
How the Royal Society’s EiR programme can help to drive UK innovation
...
Box 1
Strategic commitment
...
KOL Ambassador Program & Podcast Creation: A Customer Story
...